Abstract
Introduction: Hypertension is the leading modifiable cause of premature death and hence World Health Organization (WHO) has made it one of its global prevention priorities. It is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. The prevention and treatment of hypertension imposes a significant public health challenge owing to its related morbidity and mortality as well as the expense to society. Hypertension is referred to as a silent and an invisible killer and affects at least 1.4 billion people globally. Less than half of adults (42%) with hypertension are diagnosed and treated.
Methodology The research design was an institution based single centered, observational descriptive study, cross sectional in design and was carried out for a duration of 28 days (4 weeks) from 01.06.2024 to 29.06.2024. The study was conducted in the Outpatient Department (OPD) of Regimenal therapies, National Institute of Unani Medicine (NIUM), Bengaluru. All people above 21 years of age attending OPD constituted study population. In present study, 524 patients were included in the study. The diagnosis of hypertension was done as per WHO guidelines. Data analysis was done using SPSS version 24.
Results: The study revealed that prevalence of hypertension was 35.87% in the study population. In the present study, 53.20% of diagnosed hypertensive patients were females and rest 46.80% were males. Majority of diagnosed hypertensive patients (39.89%) belonged to the age group of above 60 years.
Conclusion: Prevalence of hypertension is significantly increasing at a greater pace globally as well as in India. Periodic screening and raising awareness about hypertension in general population is necessary to reduce the prevalence of the disease and thereby the associated morbidity and mortality.
Keywords: Hypertension, WHO, Prevalence, SPSS, OPD patients.
Publisher
Society of Pharmaceutical Tecnocrats
Reference26 articles.
1. 1. Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circulation research. 2023 Apr 14;132(8):1050-63. https://doi.org/10.1161/CIRCRESAHA.122.321762 PMid:37053276
2. 2. Whelton PK, He J, Appel LJ, et al. National High BP Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from the National High BP Education Program. JAMA. 2002;288(15):1882-1888. https://doi.org/10.1001/jama.288.15.1882 PMid:12377087
3. 3. Tackling G, Borhade MB. Tackling G, Borhade MB. Hypertensive heart disease. [Updated 2020 Jun 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK539800/
4. 4. Chia YC, Buranakitjaroen P, Chen CH, et al. Current status of home BP monitoring in Asia: statement from the HOPE Asia Network. J Clin Hypertens. 2017;19:1192-1201. https://doi.org/10.1111/jch.13058 PMid:28815840 PMCid:PMC8030958
5. 5. Kim JH, Thiruvengadam R. Hypertension in an Ageing Population: Diagnosis, Mechanisms, Collateral Health Risks, Treatments, and Clinical Challenges. Ageing Research Reviews. 2024 May 18:102344. https://doi.org/10.1016/j.arr.2024.102344 PMid:38768716